Valuation : RVL Pharmaceuticals plc

Market Cap 334K 288K 271K 247K 464K 31.73M 468K 3.21M 1.25M 16.14M 1.25M 1.23M 53.52M P/E 2021
-1.12x
P/E 2022 -1.95x
Enterprise Value 13.28M 11.46M 10.77M 9.83M 18.46M 1.26B 18.59M 128M 49.65M 641M 49.86M 48.78M 2.13B EV / Sales 2021
5.55x
EV / Sales 2022 2.49x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
1 week 0
Extreme 1.0E-6
0
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0.19
5 years 0
Extreme 1.0E-6
3.71
10 years 0
Extreme 1.0E-6
9.9
Manager TitleAgeSince
Chief Operating Officer 44 01/01/2016
Human Resources Officer - 01/01/2016
Date Insider Type Main position Quantity % Market Cap. Importance
10/19/23 A
Altchem Ltd.
SellCompany 14,122,659 12.6767%
10/19/23 A
Altchem Ltd.
SellCompany 14,122,659 12.6767%
10/18/23 A
Altchem Ltd.
SellCompany 3,421,537 3.0712%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 111
+0.21%-1.70%+1.90%+18.18% 49.81B
+2.09%-0.81%+452.73%+517.81% 44.06B
-1.09%-0.73%+35.40%+16.04% 42.99B
-0.26%-3.58%+17.19%+72.80% 40.88B
-0.48%-3.09%+17.78%+49.80% 33.11B
-1.81%-5.94%+22.65%+115.79% 16.58B
-1.06%+3.29% - - 17.27B
-1.35%-2.32%+10.40%+25.90% 14.63B
-2.05%-5.44%+72.89%+36.51% 13.76B
Average -0.58%-1.47%+78.87%+106.61% 27.31B
Weighted average by Cap. -0.25%-1.79%+95.32%+124.45%

Financials

2021 2022
Net sales 17.5M 15.1M 14.2M 12.95M 24.32M 1.66B 24.5M 168M 65.44M 845M 65.71M 64.28M 2.8B 49.72M 42.9M 40.33M 36.8M 69.1M 4.72B 69.61M 478M 186M 2.4B 187M 183M 7.96B
Net income -64.92M -56.02M -52.66M -48.05M -90.23M -6.16B -90.89M -624M -243M -3.13B -244M -238M -10.4B -51.69M -44.6M -41.93M -38.26M -71.84M -4.91B -72.37M -497M -193M -2.5B -194M -190M -8.28B
Net Debt 7.2M 6.21M 5.84M 5.33M 10.01M 684M 10.08M 69.19M 26.92M 348M 27.04M 26.45M 1.15B 12.95M 11.17M 10.5M 9.58M 17.99M 1.23B 18.12M 124M 48.41M 625M 48.6M 47.55M 2.07B
Logo RVL Pharmaceuticals plc
RVL Pharmaceuticals plc is a pharmaceutical company focused on developing and commercializing eye care and medical aesthetics products. The Company is focused on developing and commercializing products for an underserved patient population in ocular medicine and medical aesthetics. It operates in one business segment which focuses on developing and commercializing pharmaceutical products. The Company is commercializing Upneeq for treating acquired blepharoptosis (low-lying eyelids) in adults and is developing Arbaclofen ER tablets for alleviating spasticity in multiple sclerosis patients. Their healthcare provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists, and other qualified practitioners. The target patient population comprises adults with droopy or low-lying eyelids, primarily females. Its commercial operations are managed by wholly owned subsidiaries, RVL Pharmaceuticals, Inc., and RVL Pharmacy, LLC.
Employees
125
Date Price Change Volume
28/08/26 $0.000001 -.--% 2,074
  1. Stock Market
  2. Stocks
  3. RVLPQ Stock